High fat (HF) diets can induce insulin resistance (IR) by altering skeletal muscle lipid metabolism. An imbalance between fatty acid (FA) uptake and oxidation results in intramuscular lipid accumulation, which can impair the insulin-signaling cascade. Adiponectin (Ad) is an insulin sensitizing adipokine known to stimulate skeletal muscle FA oxidation and reduce lipid accumulation. Evidence of Ad resistance has been shown in obesity and following chronic HF feeding, and may contribute to lipid accumulation observed in these conditions. Whether Ad resistance precedes and is associated with the development of IR is unknown. We conducted a time course HF feeding trial for 3 days, 2 weeks or 4 weeks to determine the onset of Ad resistance and identify the ensuing changes in lipid metabolism and insulin signaling leading to IR in skeletal muscle. Adiponectin stimulated FA oxidation (+28%, p≤0.05) and ACC phosphorylation (+34%, p≤0.05) in control animals, but failed to do so in any HF fed group (i.e. as early as 3 days). By 2 weeks, plasma membrane FA transporters and intramuscular diacylglycerol (DAG) and ceramide were increased and insulin-stimulated phosphorylation of both Akt and AS160 was blunted compared to control animals. After 4 weeks of HF feeding, maximal insulin stimulated glucose transport was impaired compared to control. Taken together, our results demonstrate that an early loss of Ad's stimulatory effect on FA oxidation precedes an increase in plasmalemmal FA transporters and the accumulation of intramuscular DAG and ceramide, blunted insulin signaling and ultimately impaired maximal insulin stimulated glucose transport into skeletal muscle induced by HF diets.
Introduction
Consumption of a high-fat (HF) diet and obesity are well known contributors to the development of insulin resistance (IR) and Type 2 Diabetes. High fat diets may induce IR in part by altering lipid metabolism in skeletal muscle (19, 23, 39) . Intramuscular lipid accumulation in untrained humans and rodents is consistently associated with skeletal muscle IR, although the cause of this accumulation is controversial. Elevated lipids may be attributable to increased fatty acid (FA) uptake (15) , decreased oxidation (17, 18) , increased esterification (19) or likely an imbalance among all of these. Impaired rates of FA oxidation and oxidative capacity have been reported in skeletal muscle of obese, IR and diabetic subjects (17, 18) . Recently, increased FA uptake into the cell as a result of increased FA transporters (FAT/CD36, FABPpm) at the plasma membrane has been suggested as an important cause of HF diet induced intramuscular lipid accumulation (14, 35) .
Despite controversies as to the method of accumulation, various lipids have been shown to interfere with insulin signal transduction and subsequent translocation of GLUT 4 to the plasma membrane. Specifically, diacylglycerol (DAG) has been shown to activate protein kinase C, thereby impairing IRS-1 and PI3k activation (22) , and ceramide has been shown to inhibit phosphorylation/activation of Akt, thus diminishing Akt's stimulatory effect on GLUT 4 translocation to the plasma membrane (10) . Collectively, the imbalance between FA uptake and oxidation, resultant intramuscular lipid accumulation, diminished insulin signal transduction and impaired glucose transport are hallmarks of skeletal muscle lipotoxicity which can be induced by HF feeding.
Adiponectin (Ad) is an insulin-sensitizing cytokine known to stimulate FA oxidation (5, 13, 23 ) and glucose uptake into skeletal muscle (8) . More specifically, the globular head, gAd, which has been shown to circulate in small quantities, exerts these effects in skeletal muscle by binding to its receptor AdipoR1 (13, 20, 33) . Globular Ad stimulates AMPK, which in turn phosphorylates and inactivates ACC, thereby decreasing malonyl CoA formation and relieving inhibition on CPT-1, allowing FA to enter the mitochondria to be oxidized (33, 40) .
Circulating Ad levels are decreased in obesity (1) and evidence of Ad resistance has also been shown in peripheral tissues of obese humans and animals. In genetically obese diabetic mice, the acute stimulatory effect of Ad on AMPK in muscle is lost. This may be due, at least in part, to an observed reduction in skeletal muscle AdipoR1 mRNA (34) . In obese humans, the stimulatory effect of gAd on FA oxidation in skeletal muscle is also blunted (5, 11) . Recently, we demonstrated that following 4 weeks of feeding rats a diet high in saturated or polyunsaturated fat, gAd no longer stimulated FA oxidation; that is, both HF diets induced Ad resistance (23).
However, only the animals fed the saturated diet became IR by 4 weeks, while polyunsaturated fed animals were insulin responsive at this time point. Thus, while a HF diet can induce Ad resistance, it is unclear whether Ad resistance precedes intramuscular lipid accumulation and the development of IR.
Surprisingly, there has been virtually no examination of the early changes in muscle lipid metabolism and response to insulin sensitizing adipokines during the development of diet induced IR. Therefore, the purpose of the current study was to elucidate the time-course over which diet-induced Ad resistance develops to determine if it precedes impairments in insulin response, and identify ensuing changes in lipid metabolism and insulin signaling which may contribute to this relationship. We chose to employ a high saturated fat diet as we have previously shown this to produce both Ad resistance and impaired insulin response within a 4 week period (23). We hypothesized that 1) Ad resistance would occur first, attributable in part to decreased AdipoR1 content, followed by 2) greater FA transporter abundance at the plasma membrane, leading to 3) increased IM DAG and ceramide content, 4) impaired activation of the insulin-signaling cascade and ultimately, 5) impaired skeletal muscle glucose transport under maximal insulin stimulated conditions.
Methods:
Animals and Diets.
Upon arrival, female Sprague-Dawley rats (140-145g, Charles River, Quebec, Canada)
were assigned to individual cages in a controlled environment with a reverse 12h light-dark cycle with ad libitum access to Purina standard rodent chow and water. Following a 3-day acclimation period, rats were randomly assigned to a control (12% kcal from fat, CON), or high-fat diet (60% kcal from lard, HF) (Research Diets, New Brunswick, NJ) for 3 days, 2 weeks or 4 weeks. Highfat fed animals were pair-fed to CON rats (fed ad libitum) with respect to caloric intake on a daily basis and body mass was recorded 3 times per week. After the pre-determined length on the diets, the animals were overnight fasted prior to experimental procedures. Ethical consent for all procedures used was obtained from the Animal Care Committee at the University of Guelph.
Muscle and Blood Sampling.
Soleus Muscle
Rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (6 mg/100 g body mass) and the soleus (Sol) muscle was carefully dissected into longitudinal strips from tendon to tendon using a 27-gauge needle. The two outside strips from each Sol were then incubated under various conditions for measurement of i) glucose transport, ii) fat metabolism or iii) key signaling proteins. Due to the number of conditions in these experiments, one animal was used for metabolism measures (leg 1: glucose transport, leg 2: fat metabolism), and a second animal was used for assessment of signaling proteins (leg 1: insulin-stimulated signaling, leg 2:
gAd-stimulated signaling). The remaining piece of Sol from each leg was immediately frozen in liquid N 2 , without incubation, to determine the effects of the chronic dietary intervention on AdipoR1 protein levels or total muscle lipid content. For analysis of whole muscle lipid content, one Sol strip was subsequently freeze-dried, powdered, and cleaned of any visible connective tissue, and individual lipids (DAG and ceramide) were extracted and measured using gas-liquid chromatography as described previously (6) .
Blood
Terminal blood collection was made at the completion of the treatment via cardiac puncture after first excising skeletal muscles for incubation. A glucometer reading (Bayer Elite XL, Toronto, ON, Canada) of whole blood glucose was also made. All blood samples were collected in heparinized tubes after an overnight fast, centrifuged at 9300 x g for 5 min at 4°C, and the plasma removed for analyses of insulin (sensitive rat RIA kit, Linco, St Charles, MS) and total adiponectin (mouse RIA kit, Linco, St Charles, MS).
Preparation of Giant Sarcolemmal Vesicles
Red gastrocnemius (RG) and red tibialis anterior (RTA) muscles from each animal were pooled to prepare giant sarcolemmal vesicles as described previously (9 
AMPK/ACC and Insulin Signaling Proteins.
Soleus strips were incubated in KHB containing 4% FA-free BSA, 5 mM glucose, and 0.5 mM palmitate for either 1) 30 min in the presence or absence of gAd (2.5 µg/mL) for the determination of total and phosphorylated AMPK and ACC protein content, or ii) for 10 min in the presence or absence of insulin (10 mU/mL) for the determination of total and phosphorylated insulin signaling proteins. After incubation, the strips were immediately frozen and stored in liquid N 2 until subsequent Western Blot analyses.
Western Blot Analyses.
Muscle tissue (~ 50 mg Sol) was homogenized (5,000 µL/g tissue, 1:5 dilution) in icecold buffer suitable for protein extraction and preserving phosphorylation states of proteins as described previously (30) . Homogenates were centrifuged at 20,000 x g for 20 min at 4°C and the supernatant was removed and protein content was determined using BSA as standards. 
Calculations and Statistics.
All data are reported as mean ± SE. Results were analyzed using a randomized block design 2-way ANOVA and a Student Newman Keuls's post hoc test was used to test significant differences revealed by the ANOVA. For all muscle measurements, no differences were found between CON animals at the 3 time points, therefore the CON groups were combined. Similarly, for Western blots of total protein content, no differences were found between basal and acute stimulated conditions; therefore these groups were also combined. One-way ANOVA was used to analyze dietary and/or time effects when no additional treatment was present. Significance was accepted at p≤0.05.
Results:
Body mass and blood measurements:
There was no significant difference in pre-trial or terminal body mass of CON and HF animals at any time point (Table 1) . Fasting blood glucose and plasma insulin did not differ between CON and HF animals at any time point (Table 1) . Fasting plasma Ad was significantly lower in HF animals compared to CON animals at each time point (p≤0.05, Table 1 ).
Lipid metabolism:
FA oxidation: Basal FA oxidation rate did not differ between CON and HF rats at any time point. Adiponectin significantly increased FA oxidation in Sol from CON rats (+28%; p≤0.05), but had no stimulatory effect on FA oxidation in HF animals at any time point ( Figure   1A ).
FA esterification: FA esterification into TAG was greater in HF animals by 2 and 4 weeks compared to CON (+23%, +34% respectively, p≤0.05), but gAd did not have a significant acute effect within dietary treatments ( Figure 1B ). Fatty acid esterification into DAG was not different between the dietary treatments at any time point, and was unaffected by gAd (range, 13.1 ± 0.9 to 14.5 ± 0.5 nmol/g/hr).
Total palmitate uptake: Total palmitate uptake was greater in HF fed rats after 2 and 4 weeks compared to CON (+13% for both, p≤0.05). Treatment with gAd did not change total FA uptake in any group ( Figure 1C ).
Adiponectin stimulated signaling proteins and receptor:
AMPK and ACC Signaling: There was no significant effect of diet or acute gAd exposure on tAMPK, pAMPK (Figure 2A ) or tACC protein levels. Adiponectin acutely increased pACC in CON rats (+34%; p≤0.05), but failed to do so in HF rats at any time point ( Figure 2B ).
AdipoR1: There was no significant effect of diet or time on AdipoR1 protein content in Sol muscles ( Figure 3 ).
Sarcolemmal fatty acid transporters and muscle lipid content
Transporters: FAT/CD36 ( Figure 4A ) was significantly increased in the PM of red muscle (RG and RTA) of rats after 2 and 4 weeks of chronic HF feeding when compared to CON (+31% and +34% respectively; p≤0.05). FABPpm ( Figure 4B ) was elevated after 4 weeks of HF feeding compared to CON (+57%; p=0.06).
Muscle Lipid: Total DAG and ceramide content was not different between 3d HF and CON. However, total DAG (+19% to +25%; p≤0.05) and ceramide (+23% to +26%; p≤0.05) content was increased in Sol following 2wk and 4wk HF feeding compared to CON (Figure 4C , D). was blunted in HF animals compared to CON after only 3 days, and remained blunted at 2 and 4 weeks ( Figure 5A, B) . There was a trend (p=0.08) for insulin-stimulated Thr 642 phosphorylation of AS160 to be blunted in HF animals at 2 and 4 weeks compared to CON ( Figure 5C ).
Insulin signaling proteins

Skeletal muscle glucose transport
Basal glucose transport was not different among the dietary groups at any time point.
Insulin increased glucose transport above basal levels in all groups; this stimulation was significantly blunted only in the 4wk HF compared to all other groups ( Figure 6 ).
Discussion
Evidence of Ad resistance in skeletal muscle has been shown in diabetic mice (34), obese humans (5, 11) and following HF feeding in rats (23). However, whether Ad resistance precedes and potentially contributes to intramuscular lipid accumulation and IR is unknown. Therefore, we conducted a time course HF feeding trial in rats to determine the onset of Ad resistance and to identify the ensuing changes in lipid metabolism and insulin signaling leading to IR. Here we have shown that Ad resistance occurs very rapidly, after only 3 days of HF (saturated) feeding and is sustained, as determined by a failure of gAd to acutely stimulate FA oxidation and phosphorylate ACC in skeletal muscle of all HF fed groups. However, this was not due to a decrease in AdipoR1 protein content. By 2 weeks of HF feeding, we observed increased FAT/CD36 at the PM of skeletal muscle, accompanied by increased total FA uptake into muscle and intramuscular ceramide and DAG accumulation. Furthermore, blunted insulin-stimulated phosphorylation of both Akt and AS160 was apparent by 2 weeks, whereas impaired maximally insulin-stimulated glucose transport did not occur until 4 weeks ( Figure 7 ). Taken together, our results suggest that the early loss of gAd's stimulation of FA oxidation, coupled with a subsequent increase in FA transport, is associated with the accumulation of reactive DAG and ceramide lipid species and impaired insulin response.
High fat feeding induces adiponectin resistance prior to increases in intramuscular lipid content and impaired insulin response.
Similar to our previous study (23), we have shown that a 60% saturated fat diet can induce skeletal muscle Ad resistance, as evidenced by a failure of gAd to increase FA oxidation or phosphorylate ACC above basal levels in intact, isolated soleus muscles. However, we have now identified that this resistance occurs extremely rapidly, preceding intramuscular lipid accumulation and impairment of maximal-insulin stimulated glucose transport. Adiponectin is known to increase FA oxidation in skeletal muscle by the inactivation of ACC, and reducing inhibition of CPT1 by malonyl CoA, leading to increased FA uptake into the mitochondria (33, 40) . Whether this requires the activation of AMPK is controversial (33). As with our previous study (23), we did not show an effect of 30 min gAd exposure on pAMPK in soleus muscle of any group, but did observe a 30% increase in gAd-stimulated pACC in CON animals. This suggests that the loss of gAd-stimulated FA oxidation in HF animals may be attributable to a lack of phosphorylation of ACC, independent of changes in AMPK phosphorylation.
The decreased gAd response in HF fed animals was not attributable to a decrease in receptor content. Several studies which have examined muscle AdipoR1 in response to HF feeding have only examined mRNA levels and have reported no change (3, 4) or an increase (2, 7) following 1 to 5 months of HF feeding. Moreover, AdipoR1 mRNA is reported to be decreased in genetically obese diabetic mice (34) . Interestingly, a recent study by Weigert et. al.
(38) reported increased AdipoR1 mRNA levels in monocytes from type 2 diabetic subjects, whereas AdipoR1 protein content was actually decreased, re-enforcing the concern that changes in protein do not always parallel changes in mRNA. In the current study we did not observe any changes in whole muscle AdipoR1 protein content. Therefore, a change in receptor protein content does not appear to be a likely cause of Ad resistance. However, we cannot rule out the possibility that AdipoR1 sensitivity, conformation, or association with the PM or other required molecules could have been altered by the HF diet and contributed to the observed resistance.
Furthermore, the signaling events between gAd binding to AdipoR1 and AMPK-ACC phosphorylation are not well established. Suppressor of cytokine signaling 3 (SOCS3) has been shown to inhibit leptin activation of AMPK in cultured human myotubes and contribute to leptin resistance observed in obese subjects (32) . Since leptin and Ad stimulate FA oxidation through similar mechanisms, it is possible that SOCS3 may interfere with intracellular gAd signal transduction as well. Further research is required to determine the effects of SOCS3 on gAd signaling in skeletal muscle.
High fat feeding increases fatty acid transporter and intramuscular lipid content by 2 weeks.
Total palmitate uptake was increased above CON by 2 and 4 weeks of HF feeding, as was the rate of esterification into TAG, and total muscle DAG and ceramide contents. A likely explanation for the increased palmitate uptake is a parallel increase in FA transporters at the PM.
Specifically, PM associated FAT/CD36 protein content was increased above CON in 2 and 4wk HF and FABPpm protein content was increased above CON in 4wk HF. Thus, by 2 weeks of HF feeding, membrane associated FAT/CD36 and palmitate uptake into the muscle was increased, which, together with a diminished stimulation of FA oxidation by Ad, likely contributed to the observed accumulation of DAG and ceramide.
Clearly, the temporal data in this study cannot prove that the early development of Ad resistance is causative in the accumulation of intramuscular lipids and IR. Indeed, we (16) In comparison, impaired insulin-stimulated AS160 phosphorylation was not evident until 4wk of HF feeding. Nascimento et al (24) has reported blunted insulin stimulation of AS160 following 7 weeks of a HF diet. As AS160 is a downstream substrate of Akt, it is possible that impaired Akt activation does not translate into impaired AS160 activation until later on. To the best of our knowledge, it is unknown whether ceramide directly interferes with AS160 phosphorylation, independent of its effects on Akt.
While intramuscular lipid accumulation may partially explain the blunted phosphorylation of Akt, it is interesting that this reduction in insulin signaling occurs well before the reduction in glucose transport. To the best of our knowledge, ours is one of the first papers to show this timeline. Akt is a known intermediate necessary for GLUT 4 translocation (21).
However, a recent study by Ng et al (25) proposed the idea of Akt spareness; that is, minimal activation of Akt is sufficient to elicit a maximum effect on glucose transport and AS160
phosphorylation. Ng et al showed that the dose response of insulin-stimulated 2-deoxyglucose uptake in 3T3-L1 adipocytes paralleled the dose-response activation of AS160 phosphorylation, but not that of Akt itself. Therefore, in the current study, although Akt signaling is impaired early on, it is possible that glucose transport can be maintained, and it is not until subsequent AS160 impairment that functional impairments in glucose transport are seen. Why AS160 phosphorylation is retained longer, and the physiological significance of early impairments of insulin stimulated Akt phosphorylation remain to be determined.
Unlike the rapid development of Ad resistance, maximal insulin-stimulated glucose transport was not impaired until 4 weeks of HF feeding. While a 4 week HF feeding period is still relatively brief, we have clearly demonstrated that several significant impairments in lipid metabolism and insulin signaling occur much earlier (i.e. after 3 days), and likely contribute to the development of lipid induced IR. Although we cannot discount that impaired glucose transport may have developed prior to 4 weeks, our results confirm that following 2 weeks on a 60% high saturated diet, skeletal muscle is still fully responsive to a maximal dose of insulin. It is possible, however, that we may have observed decreased insulin sensitivity to a sub-maximal insulin dose prior to this.
Summary and Perspectives
The present study utilized a time course high saturated fat feeding model to determine the early metabolic events in skeletal muscle leading to IR. We propose that a rapid loss of gAd's stimulatory effect on FA oxidation leaves the muscle less able to adequately respond to the excess lipid it is exposed to during HF feeding. The actual cause of Ad resistance remains unknown, although a decrease in receptor number does not appear to be the cause. Regardless of the specific cause, it seems plausible that the rapid development of resistance to an insulinsensitizing cytokine, such as Ad, may be a contributing factor to the ensuing development of IR.
This inability to appropriately stimulate FA oxidation, coupled with increased FA transporters at the plasma membrane and increased rate of FA uptake, results in intramuscular lipid accumulation. Specifically, ceramide accumulation is likely involved in the observed impaired phosphorylation of Akt and AS160, eventually resulting in impaired glucose transport. It should be recognized that these findings were restricted to a high saturated fat diet, and may not represent the course of events with the feeding of a polyunsaturated fat diet. Future studies should determine the specific cause of Ad resistance to serve as a potential therapeutic target for the treatment of insulin resistance. Fasting blood glucose (mmol/l) 7.5 ± 0. 
